Anina Ratjen

Anina Ratjen

Auto-generated profile, based on publicly available information

Anina Ratjen

University of Washington, Seattle, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
PSPatrick R. Secor
Patrick R. Secor
LMLia A. Michaels
Lia A. Michaels
ARAnina Ratjen
Anina Ratjen
LJLaura K. Jennings
Laura K. Jennings
PSPradeep K. Singh
Pradeep K. Singh
Significance: Bacteria live in aggregates at sites of chronic infection, and aggregated growth is thought to be important in producing key infection phenotypes such as antibiotic tolerance. We found that entropic forces generated by polymers abundant at chronic infection sites can cause bacteria to aggregate by a mechanism known as “depletion aggregation.” This aggregation mechanism does not require biofilm formation functions, but it does cause bacteria to become much less susceptible to killing by antibiotics. These findings indicate that aggregation could be a default growth mode at infection sites. It might be useful to target mechanisms of depletion-mediated antibiotic tolerance for the treatment of chronic infections.

8 November 2017 in mBio
Verified
Journal Article
Open access
PDF file
PJPeter Jorth
Peter Jorth
KMKathryn McLean
Kathryn McLean
ARAnina Ratjen
Anina Ratjen
PSPatrick R. Secor
Patrick R. Secor
GBGilbert E. Bautista
Gilbert E. Bautista
SSStephen J. Salipante
Stephen J. Salipante
While much attention has been focused on acquired antibiotic resistance genes, chromosomal mutations may be most important in chronic infections where isolated, persistently infecting lineages experience repeated antibiotic exposure. Here, we used experimental evolution and whole-genome sequencing to investigate chromosomally encoded mutations causing aztreonam resistance in Pseudomonas aeruginosa and characterized the secondary consequences of resistance development. We identified 19 recurrently mutated genes associated with aztreonam resistance. The most frequently observed mutations affected negative transcriptional regulators of the mexAB-oprM efflux system and the target of aztreonam, ftsI . While individual mutations conferred modest resistance gains, high-level resistance (1,024 µg/ml) was achieved through the accumulation of multiple variants. Despite being largely stable when strains were passaged in the absence of antibiotics, aztreonam resistance was associated with decreased in vitro growth rates, indicating an associated fitness cost. In some instances, evolved aztreonam-resistant strains exhibited increased resistance to structurally unrelated antipseudomonal antibiotics. Surprisingly, strains carrying evolved mutations which affected negative regulators of mexAB-oprM ( mexR and nalD ) demonstrated enhanced virulence in a murine pneumonia infection model. Mutations in these genes, and other genes that we associated with aztreonam resistance, were common in P. aeruginosa isolates from chronically infected patients with cystic fibrosis. These findings illuminate mechanisms of P. aeruginosa aztreonam resistance and raise the possibility that antibiotic treatment could inadvertently select for hypervirulence phenotypes. IMPORTANCE Inhaled aztreonam is a relatively new antibiotic which is being increasingly used to treat cystic fibrosis patients with Pseudomonas aeruginosa airway infections. As for all antimicrobial agents, bacteria can evolve resistance that decreases the effectiveness of the drug; however, the mechanisms and consequences of aztreonam resistance are incompletely understood. Here, using experimental evolution, we have cataloged spontaneous mutations conferring aztreonam resistance and have explored their effects. We found that a diverse collection of genes contributes to aztreonam resistance, each with a small but cumulative effect. Surprisingly, we found that selection for aztreonam resistance mutations could confer increased resistance to other antibiotics and promote hypervirulence in a mouse infection model. Our study reveals inherent mechanisms of aztreonam resistance and indicates that aztreonam exposure can have unintended secondary effects.

6 July 2020 in Thorax
Verified
Journal Article
Closed access
PDF file
MNMaria T Nelson
Maria T Nelson
DWDaniel J Wolter
Daniel J Wolter
AEAlexander Eng
Alexander Eng
EWEli J Weiss
Eli J Weiss
AVAnh T Vo
Anh T Vo
LHLuke R Hoffman
Luke R Hoffman
Rationale: The most common antibiotic used to treat people with cystic fibrosis (PWCF) is inhaled tobramycin, administered as maintenance therapy for chronicPseudomonas aeruginosalung infections. While the effects of inhaled tobramycin onP. aeruginosaabundance and lung function diminish with continued therapy, this maintenance treatment is known to improve long-term outcomes, underscoring how little is known about why antibiotics work in CF infections, what their effects are on complex CF sputum microbiomes and how to improve these treatments.Objectives: To rigorously define the effect of maintenance tobramycin on CF sputum microbiome characteristics.Methods and measurements: We collected sputum from 30 PWCF at standardised times before, during and after a single month-long course of maintenance inhaled tobramycin. We used traditional culture, quantitative PCR and metagenomic sequencing to define the dynamic effects of this treatment on sputum microbiomes, including abundance changes in both clinically targeted and untargeted bacteria, as well as functional gene categories.Main results: CF sputum microbiota changed most markedly by 1 week of antibiotic therapy and plateaued thereafter, and this shift was largely driven by changes in non-dominant taxa. The genetically conferred functional capacities (ie, metagenomes) of subjects’ sputum communities changed little with antibiotic perturbation, despite taxonomic shifts, suggesting functional redundancy within the CF sputum microbiome.Conclusions: Maintenance treatment with inhaled tobramycin, an antibiotic with demonstrated long-term mortality benefit, primarily impacted clinically untargeted bacteria in CF sputum, highlighting the importance of monitoring the non-canonical effects of antibiotics and other treatments to accurately define and improve their clinical impact.

31 December 2020 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
CPCe Pope
Ce Pope
AVAt Vo
At Vo
HHHs Hayden
Hs Hayden
EWEj Weiss
Ej Weiss
SDS Durfey
S Durfey
LHLr Hoffman
Lr Hoffman

1 January 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ARAnina Ratjen
Anina Ratjen
YYYvonne Yau
Yvonne Yau
JWJillian Wettlaufer
Jillian Wettlaufer
LMLarissa Matukas
Larissa Matukas
JZJames E. A. Zlosnik
James E. A. Zlosnik
VWValerie Waters
Valerie Waters
Burkholderia cepacia complex and Stenotrophomonas maltophilia infections are associated with poor clinical outcomes in persons with cystic fibrosis (CF). The MIC 50 based on planktonic growth and the biofilm concentration at which 50% of the isolates tested are inhibited (BIC 50 ) of tobramycin were measured for 180 B. cepacia complex and 101 S. maltophilia CF isolates and were 100 μg/ml for both species. New inhalation devices that deliver high tobramycin levels to the lung may be able to exceed these MICs.

1 May 2019 in The Journal of Pediatrics
Verified
Journal Article
Closed access
ARAnina Ratjen
Anina Ratjen
JAJacky Au
Jacky Au
SCSusan Carpenter
Susan Carpenter
PJPhilip John
Philip John
FRFelix Ratjen
Felix Ratjen